Insider Trades That Actually Matter
Insider Trading Activity
Recent insider purchases and sales at biotech companies. Filtered to remove routine scheduled sales, option exercises, and vesting events — only conviction trades. Why insider trades matter →
How insider trade filtering works
What is SEC Form 4 insider trading?
Form 4 is filed with the SEC whenever a company insider (officer, director, or 10% shareholder) buys or sells stock. These filings are public and must be submitted within 2 business days of the transaction. They're one of the few real-time signals of management conviction.
How do you filter out noise in insider trades?
Most insider transactions are routine — option exercises, automatic vesting sales, or pre-planned 10b5-1 trades. We use AI classification to separate conviction trades (open market purchases with personal capital) from noise. Only trades flagged as meaningful appear on this page.
Why do insider buys matter more than sells?
Insiders sell for many reasons (taxes, diversification, estate planning), but they buy for only one — they believe the stock is going up. An executive spending personal cash on their own company's stock is among the strongest conviction signals in the market, especially at small-cap biotech companies.
How quickly are insider trades reported?
SEC rules require Form 4 filings within 2 business days of a transaction. We parse new filings from EDGAR as they're published, typically within hours. The filing date shown is when the SEC received the disclosure, not necessarily the transaction date.
Insider Purchases
Open-market buys with personal capital — the highest-conviction insider signal.
Most active: KOD (82 buys by Baker Bros. Advisors LP, Director)
Epstein David R
DirectorDirector
Epstein David R
DirectorDirector
Epstein David R
DirectorDirector
Kemula Pierre Thadee Victor
ExecChief Financial Officer
Kemula Pierre Thadee Victor
ExecChief Financial Officer
Kemula Pierre Thadee Victor
ExecChief Financial Officer
Knotnerus Tim Jasper
ExecChief Executive Officer
Knotnerus Tim Jasper
ExecChief Executive Officer
Posner Brian S
DirectorDirector
Williams Donald Allen
DirectorDirector
Williams Donald Allen
DirectorDirector
Coleman Glenn
ExecEVP & Chief Financial Officer
Cavers Greg
ExecChief Financial Officer
Mortimer Ian
ExecPresident & Ceo
Kelly Thomas Patrick
ExecChief Financial Officer
Insider Sales
Open-market sells (noise-filtered). Routine 10b5-1 plan trades are excluded.
Most active: GRAL (7 sales by Ofman Joshua J., Chief Executive Officer)
Bloch Stephen M
DirectorDirector
Hawkins Matthew J.
ExecChief Executive Officer
Krempa David
ExecChief Business Officer
Krikorian Lazarus
ExecSVP & Chief Accounting Officer
Garland J. Scott
DirectorDirector
Kastelein Johannes Jacob Pieter
ExecChief Scientific Officer
Foundation Fighting Blindness Retinal Degeneration Fund
DirectorDirector
Burrows Scott L
ExecChief Financial Officer
Ji Ping
DirectorDirector
Ji Ping
DirectorDirector
Sanders Corazon (Corsee) D.
DirectorDirector
Feld Michael
ExecEVP, Chief Revenue Officer
Blum Robert I
ExecPresident & CEO
Burrows Francis
ExecChief Scientific Officer
Ji Ping
DirectorDirector
Noise-filtered insider signals, in your inbox
Real insider buys only. No 10b5-1 clutter. Free every Monday.
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Smart Money Moves
New positions and exits from 20 specialist biotech funds this quarter
Want AI context on every signal? Start free trial →